Results 11 to 20 of about 8,522 (180)
Repeated Thrombolytic Therapy in Patients with Recurrent Acute Ischemic Stroke [PDF]
Journal of Stroke, 2013 Background and PurposeWidespread use of thrombolytic treatments, along with improved chances of survival after an initial ischemic stroke, increases the possibility of repeated thrombolysis. There are few reports, however, regarding repeated thrombolysis
Han Soo Yoo +9 more
doaj +1 more source
Ibrain, EarlyView., 2023 Compound porcine perebroside and ganglioside injection (CPCGI) was used to treat ischemic stroke. However, there was no clinical evidence of low‐dose CPCGI. We conducted a clinical study to analyze whether the clinical results of low‐dose and standard‐dose CPCGI in patients with ischemic stroke were different.
Ya Chen +8 more
wiley +1 more source
Research in Cardiovascular Medicine, 2016 Background: Thrombolytic therapy in patients with sub-massive pulmonaryembolism (SMPTE) needs further assessment. Objectives: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE ...
Hasan Allah Sadeghi +4 more
doaj +1 more source
Experiences of health management among people at high risk of stroke in China: A qualitative study
Nursing Open, Volume 10, Issue 2, Page 613-622, February 2023., 2023 Abstract Background Effective health management of people at high risk of stroke in China is challenging. Aim To explore and identify the experiences of health management among people at high risk of stroke in order to provide a foundation for a targeted health management strategy for this special group. Design A qualitative, descriptive study based on
Lina Guo +7 more
wiley +1 more source
Tratamento trombolítico do enfarte agudo do miocárdio. Primeira de três partes.
Acta Médica Portuguesa, 1998 I-Rationale of thrombolytic therapy in acute myocardial infarction (AMI). II-Thrombolytic drugs. III-Effects of thrombolytic therapy on mortality. IV-Studies comparing the effects of various thrombolytic agents on mortality.
J T Soares-Costa +2 more
doaj +1 more source
EVOLUTION OF THROMBOLYTIC THERAPY IN THE TREATMENT OF MYOCARDIAL INFARCTION
Рациональная фармакотерапия в кардиологии, 2015 History of thrombolytic therapy is shortly reflected, main trials of various thrombolytics in acute ST-segment elevation myocardial infarction (STEMI) are analyzed. Perspectives of modern thrombolytic therapy in patients with STEMI are discussed.
P. G. Kesov +3 more
doaj +3 more sources
Thoracic Cancer, Volume 13, Issue 24, Page 3496-3503, December 2022., 2022 Patients with T790M‐negative EGFR‐mutant advanced NSCLC received anlotinib plus platinum‐based chemotherapy after resistance to first‐ or second‐generation EGFR TKIs. The maximum tolerated dose (MTD) of anlotinib was 12 mg, and the median PFS was 5.75 (95% CI: 4.37–7.52) months.
Juan Li +7 more
wiley +1 more source
Indian Heart Journal, 2017 Objectives: Ventricular septal rupture (VSR) is a rare but feared complication after myocardial infarction (MI). The objective of this study was to investigate the effects of thrombolytic therapy on the patterns of VSR following MI.
Sunil Kumar Srinivas +3 more
doaj +1 more source
Brain Pathology, Volume 33, Issue 1, January 2023., 2023 There is no pharmacological treatment available to limit progressing neuronal death after cerebral ischemia. Here we show that targeting the interaction of GABAB receptors with CaMKII using a synthetic interfering peptide after an excitotoxic insult in cultured neurons or in brain slices from MCAO‐treated mice restored downregulated GABAB receptor ...
Karthik Balakrishnan +7 more
wiley +1 more source
Aspect of Thrombolytic Therapy: A Review
The Scientific World Journal, 2014 Thrombolytic therapy, also known as clot busting drug, is a breakthrough treatment which has saved untold lives. It has been used in the clinical area to treat venous and arterial thromboembolic complaints which are a foremost cause of death.
Md. Ramjan Ali +6 more
doaj +1 more source